iRadimed Q1 2024 Adj EPS $0.36 Beats $0.34 Estimate, Sales $17.598M Beat $17.130M Estimate
Portfolio Pulse from Benzinga Newsdesk
iRadimed (NASDAQ:IRMD) reported Q1 2024 adjusted EPS of $0.36, surpassing the $0.34 estimate, and sales of $17.598M, exceeding the $17.130M estimate. This represents a 20% increase in EPS and a 13.72% increase in sales from the same period last year.
May 02, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iRadimed reported a strong Q1 2024 with EPS and sales beating estimates, showing a 20% EPS growth and 13.72% sales growth year-over-year.
Beating both EPS and sales estimates indicates strong financial health and operational efficiency. The year-over-year growth in EPS and sales further solidifies iRadimed's market position, likely leading to positive investor sentiment and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100